Stifel Nicolaus Lowers Nyxoah (NASDAQ:NYXH) Price Target to $8.00

Nyxoah (NASDAQ:NYXH) had its price objective lowered by investment analysts at Stifel Nicolaus from $10.00 to $8.00 in a research note issued on Friday, MarketBeat.com reports. The firm presently has a “buy” rating on the stock. Stifel Nicolaus’ target price suggests a potential upside of 179.72% from the company’s previous close.

Several other equities analysts have also commented on NYXH. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $11.00 price target on shares of Nyxoah in a research report on Monday, March 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nyxoah in a research report on Monday, December 29th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $9.33.

Nyxoah Stock Down 0.3%

Shares of NASDAQ:NYXH opened at $2.86 on Friday. The stock’s 50-day moving average price is $3.80 and its two-hundred day moving average price is $4.61. The company has a current ratio of 1.25, a quick ratio of 1.16 and a debt-to-equity ratio of 0.37. Nyxoah has a 12-month low of $2.76 and a 12-month high of $8.64. The firm has a market cap of $110.85 million, a price-to-earnings ratio of -1.07 and a beta of 1.66.

Nyxoah (NASDAQ:NYXH) last issued its quarterly earnings results on Saturday, February 14th. The company reported ($0.69) earnings per share (EPS) for the quarter. Nyxoah had a negative return on equity of 139.18% and a negative net margin of 884.69%.The business had revenue of $6.62 million during the quarter. On average, research analysts forecast that Nyxoah will post -1.91 EPS for the current year.

Institutional Trading of Nyxoah

Institutional investors and hedge funds have recently bought and sold shares of the business. Raymond James Financial Inc. increased its position in Nyxoah by 35.6% during the 3rd quarter. Raymond James Financial Inc. now owns 12,762 shares of the company’s stock worth $59,000 after purchasing an additional 3,353 shares in the last quarter. Bank of America Corp DE increased its position in Nyxoah by 72.4% during the 2nd quarter. Bank of America Corp DE now owns 7,866 shares of the company’s stock worth $59,000 after purchasing an additional 3,303 shares in the last quarter. Citadel Advisors LLC acquired a new stake in Nyxoah during the 3rd quarter worth approximately $98,000. Deutsche Bank AG lifted its holdings in shares of Nyxoah by 40.0% during the 4th quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock valued at $161,000 after acquiring an additional 10,000 shares in the last quarter. Finally, Shay Capital LLC acquired a new position in shares of Nyxoah during the 2nd quarter valued at $374,000.

About Nyxoah

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.